CTLA4 and neoplasm: By conjugating PD-L1 and CTLA-4 inhibitors, as well as cytokines like IL-2, with a collagen-binding motif derived from the von Willebrand factor A3 domain, these agents can be selectively delivered to tumor sites, improving treatment specificity and efficacy 899,900.